, Tracking Stock Market Picks
Enter Symbol:
Biomed Realty Trust (BMR) [hlAlert]

up 0.26 %

Biomed Realty Trust (BMR) rated Buy with price target $21.50 by Cantor Fitzgerald

Posted on: Thursday,  Dec 20, 2012  10:25 AM ET by Cantor Fitzgerald

Cantor Fitzgerald rated Buy Biomed Realty Trust (NYSE: BMR) on 12/20/2012. Previously Cantor Fitzgerald rated Buy Biomed Realty Trust (NYSE: BMR) on
07/10/2012., when the stock price was $18.95. Since then, Biomed Realty Trust has gained 0.26% as of 10/09/2015's recent price of $19.00.
If you would have followed the previous Cantor Fitzgerald's recommendation on BMR, you would have gained 0.26% of your investment in 1186 days.

Biomed Realty Trust is focused on acquiring, owning, leasing, managing and selectively developing laboratory and office space for lease to life science tenants, including biotechnology and pharmaceutical companies, scientific research institutes, government agencies and other entities involved in the life science industry. The Company targets properties located in certain markets with established reputations as centers for scientific research, including San Diego, San Francisco, Seattle, Maryland, Pennsylvania, New York/New Jersey and Boston.

Cantor U.S. Equity Research provides timely and insightful opinions on select stocks. We look at key drivers of the stock price, including company and industry fundamentals, capital markets influences and overall economic trends to provide critical and in-depth analysis. Our focus is on small and mid-cap companies in the following sectors: * Marine Transportation * Life Sciences * Clean Technology & Energy Efficiency * Real Estate * Communications Technology * Internet * Enterprise Software
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/20/2012 10:25 AM Buy
19.45 21.50
as of 12/31/2012
1 Week down  -0.56 %
1 Month up  0.31 %
3 Months up  3.25 %
1 YTD down  -0.61 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/10/2012 9:25 AM Buy

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy